PharmaSphere: Emerging Biotechnologies Antisense RNAi Therapeutics Market Analysis
Summary
GlobalData’s PharmaSphere: Emerging Biotechnologies Antisense RNAi Therapeutics Market Analysis report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, GlobalData provides an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights into the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of RNAi therapeutics.
Highlights
Key Questions Answered
What are the drivers of the RNAi therapy field?
Who are the leading companies involved in the development of RNAi therapies?
What are the major trends in RNAi clinical trials?
What specific therapeutic areas and indications are receiving the most clinical research?
What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)?
Has investor confidence been restored in the antisense/RNAi therapy field?
Scope
This report provides market developments across the RNAi therapy field, including clinical trials, deals, and pipeline investments
Investment examined from both industry and financial communities
Clinical trials activity examined across phase of development, therapy area, and indication.
This report offers a deep dive into the synergies behind partnering and acquisition activities
Deals examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action
Pipeline profiles of 25 leading biotech companies developing RNAi therapeutics
Reasons to buy
Identify the key players in the RNAi market.
Analyze and track the strategies that companies are using to strengthen their position in the RNAi therapy field; independent source for due diligence.
Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, investment, or takeover.
Understand the flow of investment from capital markets into the RNAi therapy field.
Table Of Contents
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 13
2.1 Report Scope 13
2.2 Companies Mentioned 14
2.3 Related Reports 14
3 Antisense RNAi Therapy Overview 15
3.1 What is Antisense Therapy? 15
3.1.1 Mechanisms 16
3.2 The Second Era of RNAi 17
4 Clinical Trials 19
4.1 Overview 19
4.2 Company 20
4.3 Phase of Development 22
4.4 Therapy Area 24
4.5 Indication 27
4.5.1 Cardiovascular: Atherosclerosis 29
4.5.2 CNS: Duchenne Muscular Dystrophy 30
4.5.3 Infectious Diseases: Hepatitis Infections 32
4.6 Investigators 34
4.6.1 Specialty 34
4.6.2 Region 35
5 Company Analysis 36
5.1 Overview 36
5.1.1 Revenue 36
5.1.2 R&D Spending 37
5.1.3 Market Capitalization 38
5.2 Pipeline Profiles 39
5.2.1 Alnylam Pharmaceuticals 40
5.2.2 Antisense Therapeutics 44
5.2.3 Arrowhead Research Corporation 47
5.2.4 AuraSense Therapeutics 49
5.2.5 BioMarin Pharmaceuticals 51
5.2.6 Dicerna Pharmaceuticals 53
5.2.7 Gene Signal International SA 55
5.2.8 Idera Pharmaceuticals 56
5.2.9 InDex Pharmaceuticals AB 58
5.2.10 Isarna Therapeutics GmbH 59
5.2.11 Isis Pharmaceuticals 60
5.2.12 Miragen Therapeutics 65
5.2.13 Mirna Therapeutics 67
5.2.14 Moderna Therapeutics 68
5.2.15 Mologen AG 69
5.2.16 Oncogenex Pharmaceuticals 70
5.2.17 Quark Pharmaceuticals 72
5.2.18 Regulus Therapeutics 73
5.2.19 RXi Pharmaceuticals 75
5.2.20 Sarepta Therapeutics 76
5.2.21 Silence Therapeutics Plc 79
5.2.22 Sirnaomics 80
5.2.23 Sterna Biologicals GmbH 81
5.2.24 Sylentis SA 82
5.2.25 Tekmira (Arbutus) Pharmaceuticals 83
6 Deals Landscape 88
6.1 Overview 88
6.1.1 Geography 89
6.1.2 Entity 92
6.1.3 Company 93
6.1.4 Stage 94
6.1.5 Therapy Area 97
6.1.6 Indication 99
6.1.7 Mechanism of Action 101
6.2 Deal Type 103
6.2.1 Mergers and Acquisitions 104
6.2.2 Licensing & Partnerships 107
6.2.3 Capital Raisings 113
7 Strategic Outlook 119
8 Appendix 120
8.1 Bibliography 120
8.2 Research Methodology 120
8.2.1 Coverage 120
8.2.2 Secondary Research 121
8.3 About the Author 122
8.3.1 Adam Dion, Senior Industry Analyst 122
8.4 About GlobalData 123
8.5 Disclosure Information 123
8.6 Disclaimer 123
List Of Tables
1.1 List of Tables
Table 1: Alnylam Pharmaceuticals, Pipeline Programs, Phase I-III 41
Table 2: Alnylam Pharmaceuticals, Pipeline Programs, Preclinical 43
Table 3: Alnylam Pharmaceuticals, Pipeline Programs, Discovery 44
Table 4: Antisense Therapeutics 46
Table 5: Arrowhead Research Corporation 48
Table 6: AuraSense Therapeutics 50
Table 7: BioMarin Pharmaceuticals 52
Table 8: Dicerna Pharmaceuticals 54
Table 9: Gene Signal International SA 56
Table 10: Idera Pharmaceuticals 57
Table 11: InDex Pharmaceuticals AB 59
Table 12: Isarna Therapeutics GmbH 60
Table 13: Isis Pharmaceuticals, Pipeline Programs, Phase II-III 62
Table 14: Isis Pharmaceuticals, Pipeline Programs, Phase I 63
Table 15: Isis Pharmaceuticals, Pipeline Programs, Preclinical 64
Table 16: Miragen Therapeutics 66
Table 17: Mirna Therapeutics 67
Table 18: Moderna Therapeutics 68
Table 19: Mologen AG 70
Table 20: Oncogenex Pharmaceuticals 72
Table 21: Quark Pharmaceuticals 73
Table 22: Regulus Therapeutics 74
Table 23: RXi Pharmaceuticals 76
Table 24: Sarepta Therapeutics, Pipeline Programs, Preclinical-Phase III 78
Table 25: Sarepta Therapeutics, Pipeline Programs, Discovery 79
Table 26: Silence Therapeutics Plc 80
Table 27: Sirnaomics, Pipeline Programs, Preclinical 81
Table 28: Sterna Biologicals GmbH 82
Table 29: Sylentis SA 83
Table 30: Tekmira Pharmaceuticals, Pipeline Programs, Phase I-II 85
Table 31: Tekmira Pharmaceuticals, Pipeline Programs, Preclinical 87
Table 32: Antisense Therapy, M&A Deals Table Summary, 2010-2015 106
Table 33: Antisense Therapy, Licensing Deals Table Summary, 2010-2015 109
Table 34: Antisense Therapy, Licensing Deals Table Summary, Cont’d, 2010-2015 112
Table 35: Antisense Therapy, Capital Raisings Table Summary, 2012-2015 117
List Of Figures
1.2 List of Figures
Figure 1: Antisense Therapy Clinical Trials by Top Indications and Phase of Development 19
Figure 2: Antisense Therapy Clinical Trials (>10) by Company 20
Figure 3: Antisense Therapy Clinical Trials (<10) by Company 21
Figure 4: Antisense Therapy Clinical Trials by Company and Phase of Development 22
Figure 5: Antisense Therapy Clinical Trials by Phase of Development, 1996-2015 23
Figure 6: Antisense Therapy Clinical Trials (%) by Phase of Development, 1996-2015 23
Figure 7: Antisense Therapy Clinical Trials by Phase of Development, 2009-2015 24
Figure 8: Antisense Clinical Trials by Therapy Area 25
Figure 9: Antisense Clinical Trials, Percentage (%) by Therapy Area 26
Figure 10: Antisense Clinical Trials by Therapy Area and Phase of Development 27
Figure 11: Antisense Therapy Clinical Trials, Top Indications 28
Figure 12: Antisense Therapy Clinical Trials, Top Indications by Development Phase 28
Figure 13: Antisense Therapy Clinical Trials by Indication, Cardiovascular Disorders 30
Figure 14: Antisense Therapy Clinical Trials by Indication, CNS Disorders 31
Figure 15: Antisense Therapy Clinical Trials by Indication, Infectious Diseases 33
Figure 16: Number of Investigators by Specialty 34
Figure 17: Number of Investigators by Region 35
Figure 18: Antisense Therapy Companies by Revenue ($m), 2014 37
Figure 19: Antisense Therapy Companies by R&D Spending ($m), 2014 38
Figure 20: Antisense Therapy Companies by Market Cap ($m) 39
Figure 21: Antisense Therapy Deals, Total Deals and Deal Values ($m), 2010-2015 88
Figure 22: Antisense Therapy Deals, Deal Type Breakdown ($m), 2010-2015 89
Figure 23: Antisense Therapy Deals, Total Deals and Deal Values ($m) by Region, 2010-2015 90
Figure 24: Antisense Therapy Deals by Region (%), 2010-2015 91
Figure 25: Antisense Therapy Deals by Region, Deal Value ($m), 2010-2015 91
Figure 26: Antisense Therapy Deals by Entity Type, Private vs. Public, 2010-2015 92
Figure 27: Antisense Therapy Deals by Company, 2010-2015 93
Figure 28: Antisense Therapy Deals by Product Stage, 2010-2015 94
Figure 29: Antisense Therapy Deals, Upfront and Milestone Payments ($m), by Product Stage, 2010-2015 95
Figure 30: Antisense Therapy Deals by Product Stage (%), 2010-2015 96
Figure 31: Antisense Therapy Deals by Product Stage, Deal Value ($m), 2010-2015 97
Figure 32: Antisense Therapy Deals, Total Deals and Deal Values ($m) by Therapy Area, 2010-2015 98
Figure 33: Antisense Therapy Deals, Upfront and Milestone Payments ($m), by Therapy Area, 2010-2015 99
Figure 34: Antisense Therapy Deals by Indication, 2010-2015 100
Figure 35: Antisense Therapy Deals by Indication, Cont’d, 2010-2015 101
Figure 36: Antisense Therapy Deals by Mechanism of Action, 2010-2015 102
Figure 37: Antisense Therapy Deals by Deal Type (%), 2010-2015 103
Figure 38: Antisense Therapy, Number of M&A Deals and Deal Values ($m), 2010-2015 105
Figure 39: Antisense Therapy, Number of Licensing Deals and Deal Values ($m), 2010-2015 108
Figure 40: Antisense Therapy, Number of Capital Raisings and Deal Values ($m), 2010-2015 114
Figure 41: Antisense Therapy, Capital Raisings by Company ($m), 2010-2015 115
Figure 42: Antisense Therapy, Capital Raisings by Financial Institution ($m), 2010-2015 116
